The effect of dextromethorphan on the severity of symptoms and brain function in patients with obsessive-compulsive disorder: An ERP study
- Conditions
- obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20130518013359N6
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Patients with obsessive-compulsive disorder who have been treated with high doses of SSRI for at least 8 weeks but whose Y-BOCS index is higher than cut-off 15.People aged 18 to 60 yearsObtain patient informed consent
People aged 18 to 60 years
Obtain patient informed consent
Pregnancy or breastfeeding
Using serotonergic drugs other than SSRIs
Use of NMDA receptor antagonists other than memantine and dextromethorphan
Major Depressive Disorder (Based on DSM-IV-TR Criteria)
Psychotic and bipolar disorders (based on DSM-5 criteria)
Other anxiety disorders (such as panic disorder, post-traumatic stress disorder (PTSD), general anxiety disorder (GAD)
Abuse or dependence on drugs or alcohol
Liver dysfunction (LFT> 3ULN)
Kidney dysfunction (GFR <60 ml / kg / min)
Thyroid Disorders (Based on Thyroid Function Test)
History of seizures
Cognitive-behavioral therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changing of the latency and amplitude of brainwave components in the ERP study. Timepoint: Before intervention and 1 month, 2 months and 3 months after intervention. Method of measurement: Yale–Brown Obsessive Compulsive Scale.
- Secondary Outcome Measures
Name Time Method Changes in quantitative electroencephalography (QEEG). Timepoint: Before intervention and 3 months after intervention. Method of measurement: Quantitative Electroencephalogram.